› 6qfc

X-ray diffraction
1.96Å resolution

Structure of an anti-Mcl1 scFv

Released:
DOI: 10.2210/pdb6qfc/pdb
PDB entry 6qfc coloured by chain, front view.
PDB entry 6qfc coloured by chain, side view.
PDB entry 6qfc coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1.
Luptak J, Bista M, Fisher D, Flavell L, Gao N, Wickson K, Kazmirski SL, Howard T, Rawlins PB, Hargreaves D
Acta Crystallogr D Struct Biol 75 1003-1014 (2019)
PMID: 31692474

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-211953 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Induced myeloid leukemia cell differentiation protein Mcl-1 Chain: A
Molecule details ›
Chain: A
Length: 162 amino acids
Theoretical weight: 18.23 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q07820 (Residues: 174-327; Coverage: 44%)
Gene names: BCL2L3, MCL1
Sequence domains: Apoptosis regulator proteins, Bcl-2 family
scFv55 Chain: B
Molecule details ›
Chain: B
Length: 255 amino acids
Theoretical weight: 26.43 KDa
Source organism: Homo sapiens
Expression system: Cricetulus griseus

Ligands and Environments

1 bound ligand:
Ligand DMS 5 x DMS
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: DIAMOND BEAMLINE I03
Spacegroup: C2
Unit cell:
a: 142.852Å b: 40.458Å c: 76.237Å
α: 90° β: 110.55° γ: 90°
R-values:
R R work R free
0.194 0.193 0.219
Expression systems:
  • Escherichia coli
  • Cricetulus griseus

Quick links

Citations

1 citations in other articles

Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival Bcl-2 family proteins.
Wang et al. (2023)

1 mention without citation

Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1.
Luptak et al. (2019)